Better Decisions Begin Earlier

We help biotechnology companies, investors, and executive leaders make higher-confidence decisions by integrating science, patients, evidence, market access, and commercial strategy.

Our Philosophy

Challenge assumptions. Uncover Opportunity.

See

Connect

Integrate science, patients, evidence, market access, and commercial strategy.

Decide

Move forward with confidence

Why Divergent?

Independent Perspective

Objective strategic advice.

Commercial Intelligence

Connecting science to commercial success.

Cross-Functional Expertise

Commercial, Market Access, Medical Affairs, HEOR, Executive Operations, Business Operations

Execution Focus

Recommendations built for action.

Meet the Founder

Megan Teynor, ScD, MBA

  • 15+ years of life sciences leadership

  • Rare Disease

  • Commercial Strategy

  • Market Access & HEOR

  • Medical Affairs & Evidence Generation

  • Corporate & Portfolio Strategy

  • Executive Leadership & Operations

  • Launch Planning & Commercialization

  • Board & Executive Advisory

Science. Strategy. Commercialization.

Megan Teynor is the Founder and Principal of Divergent BioStrategies, where she advises biotechnology companies, investors, and executive leadership teams on commercialization strategy, indication prioritization, value and evidence strategy, and portfolio decision-making.

Her career has spanned nearly two decades across corporate strategy, market access, medical affairs, HEOR, evidence generation, commercialization, and executive leadership, helping organizations evaluate opportunities, prioritize investments, and maximize the commercial potential of innovative therapies.

Megan's perspective is shaped by a unique combination of scientific rigor, business strategy, and real-world execution. She earned a Doctor of Science (ScD) from the Harvard School of Public Health and a MBA from the Isenberg School of Management at UMass Amherst, bringing together deep analytical thinking with practical commercial leadership.

She founded Divergent BioStrategies with a simple belief:

The best scientific opportunity isn't always the best strategic opportunity.

Better decisions begin earlier.